Perdoceo (PRDO) Q1 2026 Earnings Transcript

Perdoceo Education delivered a solid Q1 beat with net income of $54 million, diluted EPS of $0.85, and revenue of $221.7 million, up 30.8%, 30.8%, and 4.1% year over year, respectively. Management raised full-year 2026 guidance for adjusted operating income to $254 million-$263 million and adjusted EPS to $3.05-$3.16, while continuing dividend payments and buybacks, with $91.9 million still authorized for repurchases. Growth was supported by higher CTU and St. Augustine enrollments, AI-driven student engagement efforts, and no expected material enrollment impact from changes to federal graduate loan programs.

Analysis

The setup is less about a one-quarter beat and more about a self-funding growth flywheel: retention is doing enough work that management can raise spend in marketing, tech, and program expansion without impairing margin. That matters because the business is now converting incremental enrollment into cash at a high rate, which should keep buybacks and dividends intact even if top-line growth moderates. The market may be underestimating how much operating leverage can still come from mix — especially if higher-value healthcare programs keep scaling faster than the core online segment.

The biggest second-order beneficiary is the company’s capital return policy. With a large cash balance and limited capex needs, every basis point of improvement in bad debt or retention drops disproportionately to EPS, while repurchases can continue to offset the dilution from compensation and normalize per-share growth above operating growth. That creates a setup where the stock can rerate even without an aggressive revenue surprise, particularly if the market begins to treat cash yields and buyback pace as a floor under valuation.

The main risk is that the current narrative is too dependent on continued benign regulation and steady student demand. The reported confidence around financing access and the tax benefit in next quarter’s EPS guidance could mask a more normalized underlying run-rate later this year, so the next inflection is likely the Q2/Q3 print rather than the annual guide. If retention slips, or if marketing efficiency deteriorates as spend rises, the earnings multiple can compress quickly because this is still a policy-sensitive education name, not a secular compounder.

Contrarian angle: the market may be discounting the quality of the healthcare segment because it is still small relative to the legacy online franchise, but that segment is the clearest path to a longer-duration growth story and a better valuation framework. If St. Augustine continues compounding at a double-digit profit rate into 2027, PRDO could transition from a cash-yield story to a modest growth-plus-capital-return compounder. That is the bull case the consensus is probably not fully underwriting yet.

Key Decisions for Investors

• Long PRDO into the next 1-2 earnings prints: thesis is that cash-backed buybacks and healthcare-led mix shift can sustain per-share EPS growth above revenue growth; target a 10-15% upside rerate if management reiterates 2026 execution.
• Buy PRDO on pullbacks toward the ex-dividend window and add ahead of Q2 results; use a tight stop if retention or enrollment commentary weakens, because the stock’s multiple is vulnerable to even small demand disappointments.
• Pair trade: long PRDO / short a higher-beta education peer with weaker balance sheet or more regulation exposure for a 3-6 month relative-value setup; PRDO offers cleaner cash conversion and better downside support from capital returns.
• Consider a covered-call overwrite on a PRDO long position into Q2 if implied volatility spikes; the near-term upside is likely capped by the one-time tax benefit in guidance, while the dividend provides carry.
• If you want convexity, buy modest out-of-the-money calls into the next print rather than chase common stock here; the stock can gap on any evidence that St. Augustine is becoming a larger share of earnings.